×
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)

Best Stocks Under $1.00 for 2022

The stock market has had an incredible bull-run since the Great Recession of 2008 and 2009. Stocks continue to hit new all-time highs and the price-to-earnings ratios of most S&P 500 companies look very expensive. Many investors are having trouble finding low-priced stocks that haven't already appreciated greatly during the last decade. It's hard to find a good deal on Wall Street right now when even small S&P 500 companies are trading at market caps above $1 billion.

Stocks have gotten expensive both in-terms of share price and their valuation relative to earnings. In more normal markets, a typical S&P 500 company has traded at about fifteen times their earnings. Most stocks are currently trading closer to 25 times their annual earnings. While the stock market has become more expensive as a whole, there are still a handful of undervalued stocks that are trading at less than $1.00 per share.

Value investing opportunities do exist if you're looking in the right places. Putting together a list of the best stocks under $1.00 requires investors to look at smaller and riskier companies and in sectors that are either undiscovered or unloved by the market as a whole. Some of these cheap stocks may not look especially attractive today, but long-term investors will profit if they are willing to exercise patience and hold on to shares of these comapnies through multiple economic cycles.

Some of these companies are solid investing ideas because they are too little and considered too risky to attract the interest of most managed mutual funds and Wall Street money managers. Others operate in unloved and untested areas of the market. You may find even find crypto stocks, marijuana stocks and bitcoin stocks on this list. Others have been beat up by Mr. Market after a long period of slowing profits, but are now actively trying to turn around their business and bounce back. These low-priced stocks operate in a lot of different industries, but these picks all carry two common characteristics. They all have a super-low share price of $1.00 or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.


Cidara Therapeutics logo

#1 - Cidara Therapeutics

NASDAQ:CDTX
Stock Price: $0.52 (-$0.03)
PE Ratio: -0.72
Market Cap: $35.91 million
Average Trading Volume: 310,892 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $6.45 (1,140.4% Upside)
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
Greenlane logo

#2 - Greenlane

NASDAQ:GNLN
Stock Price: $0.25 (-$0.01)
PE Ratio: -0.30
Market Cap: $30.42 million
Average Trading Volume: 1.79 million shares
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $3.22 (1,186.7% Upside)
Greenlane Holdings, Inc. develops and distributes cannabis accessories, child-resistant packaging, vape solutions, and lifestyle products in the United States, Canada, and Europe. It operates through two segments, Consumer Goods and Industrial Goods. The company provides consumption accessories, vaporizers, pipes, rolling papers and packaging, grinders, and apparel lines, as well as bubblers, rigs, and other smoking and vaporization related accessories and merchandise. It offers its products under the VIBES rolling papers, Pollen Gear, the Marley Natural accessory line, Aerospaced & Groove grinders, Marley Natural, K. Haring Glass Collections, Eyce silicone pipes, Higher Standards, and DaVinci vaporizers brands. The company also operates e-commerce websites, such as Vapor.com, Higherstandards.com, Aerospaced.com, DaVincivaporizer.com, Harringglass.com, Eycemolds.com, Vapor.ca, Vaposhop.com, and Puffitup.com. It serves customers through a network of 8,500 smoke shops, cannabis dispensaries, and specialty retailers. Greenlane Holdings, Inc. was founded in 2005 and is headquartered in Boca Raton, Florida.
Clarus Therapeutics logo

#3 - Clarus Therapeutics

NASDAQ:CRXT
Stock Price: $0.39 (-$0.02)
Market Cap: $20.36 million
Average Trading Volume: 7.83 million shares
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $7.90 (1,918.4% Upside)
Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.
Syros Pharmaceuticals logo

#4 - Syros Pharmaceuticals

NASDAQ:SYRS
Stock Price: $0.89 (-$0.13)
PE Ratio: -0.58
Market Cap: $56.00 million
Average Trading Volume: 780,120 shares
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $14.60 (1,537.9% Upside)
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
Mogo logo

#5 - Mogo

NASDAQ:MOGO
Stock Price: $0.95 (+$0.10)
PE Ratio: -1.53
Market Cap: $72.92 million
Average Trading Volume: 539,988 shares
Consensus Rating: Buy (3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $6.40 (573.7% Upside)
Mogo Inc. operates as a financial technology company in Canada and internationally. The company provides digital solutions to the consumers to get in control of their financial health. It offers Mogo app to access a digital spending account with Mogo Visa Platinum Prepaid Card; MogoCrypto that enables the buying and selling of bitcoin; MogoProtect, a free ID fraud protection and monthly credit score monitoring; MogoMortgage, a digital mortgage experience; and MogoMoney that provides access to personal loans. The company also offers Mogo Trade, a free stock trading platform with real-time stock quotes and funding; and Mogo Ventures to manage its existing investments in strategic partners and companies. In addition, it operates Carta, a digital payments software platform that enable financial technology companies, banks, and corporations to issue payment products to consumers via multiple channels, including physical, virtual, and tokenized cards, as well as payment switching and routing services. Mogo Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
Sientra logo

#6 - Sientra

NASDAQ:SIEN
Stock Price: $1.00 (-$0.02)
PE Ratio: -1.01
Market Cap: $62.33 million
Average Trading Volume: 725,841 shares
Consensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $7.41 (644.2% Upside)
Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products in the United States and internationally. It offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra Round, Sientra Teardrop, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. The company also provides body contouring products; facial and nasal implants; saline filled sizers. It serves to hospitals, surgery centers, plastic surgeons, dermatologists and other specialties. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Santa Barbara, California.
Unity Biotechnology logo

#7 - Unity Biotechnology

NASDAQ:UBX
Stock Price: $0.59 (-$0.01)
PE Ratio: -0.55
Market Cap: $41.09 million
Average Trading Volume: 685,980 shares
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $6.40 (977.4% Upside)
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
Applied Genetic Technologies logo

#8 - Applied Genetic Technologies

NASDAQ:AGTC
Stock Price: $0.62 (-$0.21)
PE Ratio: -0.42
Market Cap: $31.30 million
Average Trading Volume: 527,983 shares
Consensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $15.00 (2,331.1% Upside)
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, LLC; and Otonomy, Inc. Applied Genetic Technologies Corporation was incorporated in 1999 and is headquartered in Alachua, Florida.
Infinity Pharmaceuticals logo

#9 - Infinity Pharmaceuticals

NASDAQ:INFI
Stock Price: $0.74 (-$0.10)
PE Ratio: -1.41
Market Cap: $65.53 million
Average Trading Volume: 925,349 shares
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $6.83 (829.7% Upside)
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.
Fortress Biotech logo

#10 - Fortress Biotech

NASDAQ:FBIO
Stock Price: $0.88 (-$0.06)
PE Ratio: -1.03
Market Cap: $94.82 million
Average Trading Volume: 600,722 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $11.00 (1,146.0% Upside)
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.
Petrofac logo

#11 - Petrofac

OTCMKTS:POFCY
Stock Price: $0.75 (-$0.03)
Market Cap: $781.74 million
Average Trading Volume: 4,366 shares
Consensus Rating: Moderate Buy (6 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $160.00 (21,233.3% Upside)
Petrofac Limited designs, builds, manages, and maintains infrastructure for the energy industries in the United Kingdom, Algeria, Thailand, Oman, Kuwait, Iraq, the United Arab Emirates, the Netherlands, and internationally. It operates through three segments: Engineering & Construction (E&C); Asset Solutions; and Integrated Energy Services (IES). The E&C segment provides onshore and offshore engineering, procurement, construction, installation, and commissioning services. The Asset Solutions segment offers concept, feasibility, and front-end engineering design services, as well as manages and maintains onshore and offshore operations. The IES segment provides an integrated services for clients under flexible commercial models that are aligned with their requirements. Petrofac Limited was founded in 1981 and is based in St Helier, Jersey.
Cybin logo

#12 - Cybin

OTCMKTS:CYBN
Stock Price: $0.59 (+$0.03)
PE Ratio: -1.89
Market Cap: $97.52 million
Average Trading Volume: 740,129 shares
Consensus Rating: Moderate Buy (5 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $9.31 (1,485.4% Upside)
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a discovery-phase phenethylamine derivative to treat neuroinflammation and psychiatric conditions. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
Aptinyx logo

#13 - Aptinyx

NASDAQ:APTX
Stock Price: $0.45 (+$0.02)
PE Ratio: -0.38
Market Cap: $30.13 million
Average Trading Volume: 361,013 shares
Consensus Rating: Moderate Buy (5 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $4.67 (948.7% Upside)
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase II clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.
Skylight Health Group logo

#14 - Skylight Health Group

NASDAQ:SLHG
Stock Price: $0.55 (+$0.01)
Market Cap: $21.73 million
Average Trading Volume: 111,642 shares
Consensus Rating: Moderate Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $5.50 (900.0% Upside)
Skylight Health Group Inc. operates as a healthcare services and technology company in the United States, Canada, the United Kingdom, and Colombia. It operates the US multi-state primary care health network, which provides a range of services from primary care, sub-specialty, allied health, and laboratory/diagnostic testing. The company also owns and operates a proprietary electronic health record system that supports the delivery of care to patients through telemedicine and other remote monitoring system integrations. In addition, it offers a disruptive subscription-based telemedicine service for the un/under-insured population. The company was formerly known as CB2 Insights Inc. and changed its name to Skylight Health Group Inc. in November 2020. Skylight Health Group Inc. was founded in 2014 and is headquartered in Mississauga, Canada.
UpHealth logo

#15 - UpHealth

NYSE:UPH
Stock Price: $0.59 (+$0.03)
PE Ratio: -0.23
Market Cap: $84.87 million
Average Trading Volume: 688,908 shares
Consensus Rating: Moderate Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $8.38 (1,319.5% Upside)
UpHealth, Inc. operates as a digital health services company. It provides a patient-centric digital health technologies and tech-enabled services to manage health and integrate care in the areas of integrated care management, virtual care infrastructure, and services. The company's solutions include Syntranet Core Platform, an integrated care management platform; Cloudbreak, a provider of unified telemedicine solutions and digital health tools; HelloLyf from Glocal, a platform that delivers primary care and specialty consultations; and MedQuest Pharmacy, a full-service retail and compounding licensed pharmacy that dispenses prescribed medications shipped directly to patients. UpHealth, Inc. is headquartered in Delray Beach, Florida.
CubicFarm Systems logo

#16 - CubicFarm Systems

OTCMKTS:CUBXF
Stock Price: $0.30 (-$0.02)
Average Trading Volume: 12,565 shares
Consensus Rating: Moderate Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $1.35 (352.7% Upside)
CubicFarm Systems Corp. develops, manufactures, and sells cubic farming systems for farmers worldwide. The company offers CubicFarm System and CubicFarms' HydroGreen Grow System. Its systems help farmers to produce lettuce, basil, microgreens, nutraceutical ingredients, and animal feed. The company was formerly known as Forty Foot Farms Ltd. and changed its name to CubicFarms Systems Corp. in June 2016. CubicFarms Systems Corp was incorporated in 2015 and is headquartered in Langley, Canada.
Centamin logo

#17 - Centamin

OTCMKTS:CELTF
Stock Price: $1.00 (-$0.01)
Market Cap: $1.15 billion
Average Trading Volume: 13,132 shares
Dividend Yield: 9.98%
Consensus Rating: Moderate Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $124.00 (12,362.3% Upside)
Centamin plc engages in the exploration, mining, and development of precious metals in Egypt, Burkina Faso, Côte d'Ivoire, Jersey, the United Kingdom, and Australia. The company explores for gold deposits. Its principal asset is the Sukari Gold Mine project, which covers an area of approximately 160 square kilometers located in the Eastern Desert of Egypt. The company was incorporated in 2011 and is headquartered in Saint Helier, Jersey.
China Overseas Property logo

#18 - China Overseas Property

OTCMKTS:CNPPF
Stock Price: $0.90
Average Trading Volume: 1,914 shares
Consensus Rating: Moderate Buy (3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: N/A
China Overseas Property Holdings Limited, an investment holding company, provides property management services in Hong Kong, Macau, and the People's Republic of China. It operates through Property Management Services, Value-Added Services, and Car Parking Spaces Trading Business segments. The Property Management Services segment offers security, repair and maintenance, cleaning, and garden landscape maintenance services to mid-to high-end residential communities, commercial properties, government properties, and construction sites. The Value-Added Services segment offers engineering, vetting of building plans, facilities and equipment evaluation proposals, pre-delivery, move-in assistance, delivery inspection, engineering service quality monitoring and consulting services, etc. for property developers and other property management companies; and community asset management services and living service operations for residents, as well as commercial service operations. The Car Parking Spaces Trading Business segment engages in the trading of various car parking spaces. It is also involved in the provision of automation and other equipment upgrade services; property agency; information technology services; and service through online to offline platform. The company was formerly known as China Overseas Management Services International Limited and changed its name to China Overseas Property Holdings Limited in May 2015. The company was founded in 1986 and is headquartered in Hong Kong, Hong Kong. China Overseas Property Holdings Limited is a subsidiary of China Overseas Holdings Limited.
IMV logo

#19 - IMV

NASDAQ:IMV
Stock Price: $0.74 (+$0.04)
PE Ratio: -1.45
Market Cap: $60.72 million
Average Trading Volume: 106,391 shares
Consensus Rating: Moderate Buy (3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $2.29 (210.7% Upside)
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Eloxx Pharmaceuticals logo

#20 - Eloxx Pharmaceuticals

NASDAQ:ELOX
Stock Price: $0.24 (-$0.01)
PE Ratio: -0.26
Market Cap: $20.71 million
Average Trading Volume: 222,102 shares
Consensus Rating: Moderate Buy (3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $2.52 (954.4% Upside)
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.